(SAGE) - Earnings & Price History

SAGE: - 61.71, $2.39B, -1.57 (-2.48%)

Sector: Healthcare - Industry: Biotechnology

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. The companys lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). It is also conducting an additional Phase II exploratory trial of SAGE-547 in the treatment of severe post-partum depression (PPD). In addition, its pipeline includes next-generation product candidates, such as SAGE-217, a novel neuroactive steroid, which is in Phase I clinical trial for the treatment of orphan epilepsies and essential tremor, as well as for PPD; and SAGE-689, an acute adjunctive IV therapy for the treatment of indications where a high degree of anti-seizure activity and sedati

Past SAGE reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2014-11-13Sage Therapeutc-0.47-0.535.4435.0635.1934.8336.060.37%0.71%1.08%71.30K

Login | Register
Saturday May 26, 2018   EST
Enter a Ticker:

Economic Calendar

Durable Goods Orders 8:30 AM ET Consumer Sentiment 10:00 AM ET Charles Evans Speaks 11:45 AM ET Raphael Bostic Speaks 11:45 AM ET Robert Kaplan Speaks 11:45 AM ET Baker-Hughes Rig Count 1:00 PM ET SIFMA Rec. Early Close 2:00 ET  

AAII Sentiment Survey

BULL^ neut ^ BEAR


index chart
index color